MEF2D and acute lymphoblastic leukemia: Both the 5-year event-free survival (EFS) and overall survival (OS) rates are significantly lower in patients with MEF2D fusion than in other ALL patients, indicating that MEF2D fusion is significantly associated with ALL prognosis (Gu et al. 2016; Zhang and Meng 2022; Ohki et al. 2019).